Biodexa Pharmaceuticals (BDRX)
Biodexa Pharmaceuticals Statistics
Share Statistics
Biodexa Pharmaceuticals has 1.45K shares outstanding. The number of shares has increased by 145.69% in one year.
Shares Outstanding | 1.45K |
Shares Change (YoY) | 145.69% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | n/a |
Shares Floating | 4.9M |
Failed to Deliver (FTD) Shares | 1.11K |
FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 6.53K, so 1.12% of the outstanding shares have been sold short.
Short Interest | 6.53K |
Short % of Shares Out | 1.12% |
Short % of Float | 0% |
Short Ratio (days to cover) | 0.38 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -85.8. Biodexa Pharmaceuticals's PEG ratio is 0.
PE Ratio | 0 |
Forward PE | -85.8 |
PS Ratio | 0.01 |
Forward PS | 0.7 |
PB Ratio | 0 |
P/FCF Ratio | 0 |
PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Biodexa Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.1.
Current Ratio | 1.26 |
Quick Ratio | 1.26 |
Debt / Equity | 0.1 |
Debt / EBITDA | -0.06 |
Debt / FCF | -0.07 |
Interest Coverage | -195.46 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $18.14K |
Profits Per Employee | $-337.1K |
Employee Count | 21 |
Asset Turnover | 0.04 |
Inventory Turnover | n/a |
Taxes
Income Tax | -406K |
Effective Tax Rate | 5.42% |
Stock Price Statistics
The stock price has increased by -94.62% in the last 52 weeks. The beta is 1.5, so Biodexa Pharmaceuticals's price volatility has been higher than the market average.
Beta | 1.5 |
52-Week Price Change | -94.62% |
50-Day Moving Average | 3.22 |
200-Day Moving Average | 8.81 |
Relative Strength Index (RSI) | 35.54 |
Average Volume (20 Days) | 1.57M |
Income Statement
In the last 12 months, Biodexa Pharmaceuticals had revenue of 381K and earned -7.08M in profits. Earnings per share was -224.13.
Revenue | 381K |
Gross Profit | -3.69M |
Operating Income | -8.01M |
Net Income | -7.08M |
EBITDA | -7.16M |
EBIT | -7.44M |
Earnings Per Share (EPS) | -224.13 |
Balance Sheet
The company has 5.97M in cash and 464K in debt, giving a net cash position of 5.51M.
Cash & Cash Equivalents | 5.97M |
Total Debt | 464K |
Net Cash | 5.51M |
Retained Earnings | -144.77M |
Total Assets | 13.97M |
Working Capital | 4.04M |
Cash Flow
In the last 12 months, operating cash flow was -6.83M and capital expenditures -263K, giving a free cash flow of -7.09M.
Operating Cash Flow | -6.83M |
Capital Expenditures | -263K |
Free Cash Flow | -7.09M |
FCF Per Share | -224.44 |
Margins
Gross margin is -967.45%, with operating and profit margins of -2103.41% and -1858.01%.
Gross Margin | -967.45% |
Operating Margin | -2103.41% |
Pretax Margin | -1964.57% |
Profit Margin | -1858.01% |
EBITDA Margin | -1879.53% |
EBIT Margin | -2103.41% |
FCF Margin | -1860.63% |
Dividends & Yields
BDRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for BDRX.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 4, 2024. It was a backward split with a ratio of 1:25.
Last Split Date | Oct 4, 2024 |
Split Type | backward |
Split Ratio | 1:25 |
Scores
Altman Z-Score | -17.88 |
Piotroski F-Score | 1 |